NCT01590160

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: University College, London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Malignant pleural mesothelioma (MPM) is a rapidly lethal cancer arising from the parietal pleural mesothelium, and is associated with exposure to asbestos. Once a rare disease, it is increasing in incidence in the UK and is presently more common than cervical cancer. MPM is characterized by local invasion of adjacent structures including the chest wall, mediastinum, diaphragm and pericardium resulting in progressive shortness of breath. Median survival with best supportive care alone is approximately 6-9 months and most cases of mesothelioma present in the advanced setting. Therefore this trial will be looking at whether a new drug, Ganetespib has any improvement on survival for these types of patients.

Conditions

• Lung Cancer - Malignant Pleural Mesothelioma

Interventions

Type	Name	Description
DRUG	Ganetespib	IV, Using dose from Phase I

Timeline

• Start date: 2013-08-01
• Primary completion: 2019-11-05
• Completion: 2019-11-05
• First posted: 2012-05-02
• Last updated: 2019-11-13

Locations

1 site across 1 country: United Kingdom